Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016
Published Jun 08, 2016
44 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections
- The report reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections therapeutics and enlists all their major and minor projects
- The report assesses Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections
-

  
Source:
Document ID
GMDHC8209IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Overview61
Therapeutics Development72
  Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Overview71
  Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Comparative Analysis81
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Therapeutics under Development by Companies91
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Therapeutics under Investigation by Universities/Institutes101
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Pipeline Products Glance112
  Clinical Stage Products111
  Early Stage Products121
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Products under Development by Companies131
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Products under Investigation by Universities/Institutes141
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Companies Involved in Therapeutics Development154
  CrystalGenomics, Inc.151
  Debiopharm International SA161
  iNtRON Biotechnology Inc.171
  Wockhardt Limited181
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Therapeutics Assessment199
  Assessment by Monotherapy Products191
  Assessment by Target202
  Assessment by Mechanism of Action222
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Drug Profiles2810
  CG-400549 - Drug Profile281
    Product Description281
    Mechanism of Action281
    R&D Progress281
  Debio-1450 - Drug Profile291
    Product Description291
    Mechanism of Action291
    R&D Progress291
  Epidermicin NI-01 - Drug Profile301
    Product Description301
    Mechanism of Action301
    R&D Progress301
  SAL-200 - Drug Profile311
    Product Description311
    Mechanism of Action311
    R&D Progress312
  Small Molecule to Target Bacterial Cell Wall for MRSA and VRSA Infections - Drug Profile331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile341
    Product Description341
    Mechanism of Action341
    R&D Progress341
  Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile351
    Product Description351
    Mechanism of Action351
    R&D Progress351
  SP-2078 - Drug Profile361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  WCK-4086 - Drug Profile371
    Product Description371
    Mechanism of Action371
    R&D Progress371
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Recent Pipeline Updates383
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects411
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Discontinued Products421
Appendix432
  Methodology431
  Coverage431
  Secondary Research431
  Primary Research431
  Expert Panel Validation431
  Contact Us431
  Disclaimer441

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Vancomycin-Resistant-Staphylococcus-aureus-VRSA-Infections-Pipeline-Review-H1-2016-2088-15930>
  
APA:
Global Markets Direct - Market Research. (2016). Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Vancomycin-Resistant-Staphylococcus-aureus-VRSA-Infections-Pipeline-Review-H1-2016-2088-15930>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.